

# Scott D Berkowitz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6906787/publications.pdf>

Version: 2024-02-01

172  
papers

28,819  
citations

17405

63  
h-index

4978

167  
g-index

183  
all docs

183  
docs citations

183  
times ranked

17562  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 883-891.  | 13.9 | 8,006     |
| 2  | Oral Rivaroxaban for Symptomatic Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2010, 363, 2499-2510.   | 13.9 | 2,807     |
| 3  | Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2012, 366, 1287-1297.  | 13.9 | 2,080     |
| 4  | Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.  | 13.9 | 1,745     |
| 5  | Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. <i>Lancet, The</i> , 2009, 373, 1673-1680.  | 6.3  | 898       |
| 6  | Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. <i>New England Journal of Medicine</i> , 2018, 378, 2191-2201.   | 13.9 | 730       |
| 7  | Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia. <i>Circulation</i> , 2001, 103, 1838-1843.  | 1.6  | 661       |
| 8  | Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2017, 376, 1211-1222.   | 13.9 | 577       |
| 9  | Rivaroxaban in Peripheral Artery Disease after Revascularization. <i>New England Journal of Medicine</i> , 2020, 382, 1994-2004.  | 13.9 | 566       |
| 10 | Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. <i>Thrombosis Journal</i> , 2013, 11, 21.  | 0.9  | 471       |
| 11 | Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 205-218.   | 6.3  | 426       |
| 12 | Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement. <i>New England Journal of Medicine</i> , 2003, 349, 1703-1712.  | 13.9 | 317       |
| 13 | Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 681.  | 3.8  | 274       |
| 14 | Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. <i>European Heart Journal</i> , 2015, 36, 288-296.  | 1.0  | 266       |
| 15 | Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. <i>Thrombosis and Haemostasis</i> , 2011, 105, 444-453.  | 1.8  | 250       |
| 16 | Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. <i>Lancet Haematology, the</i> , 2014, 1, e37-e46. | 2.2  | 244       |
| 17 | Factors Associated With Major Bleeding Events. <i>Journal of the American College of Cardiology</i> , 2014, 63, 891-900.  | 1.2  | 212       |
| 18 | Allogeneic Blood Transfusions and Postoperative Infections After Total Hip or Knee Arthroplasty. <i>Journal of Bone and Joint Surgery - Series A</i> , 2014, 96, 272-278.   | 1.4  | 197       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Incidence and Predictors of Bleeding After Contemporary Thrombolytic Therapy for Myocardial Infarction. <i>Circulation</i> , 1997, 95, 2508-2516.  | 1.6 | 194       |
| 20 | Acute Profound Thrombocytopenia After c7E3 Fab (Abciximab) Therapy. <i>Circulation</i> , 1997, 95, 809-813.  | 1.6 | 193       |
| 21 | Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty. <i>Annals of Internal Medicine</i> , 2002, 137, 648.  | 2.0 | 187       |
| 22 | Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban. <i>Stroke</i> , 2014, 45, 1304-1312.  | 1.0 | 187       |
| 23 | Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 651-658.   | 1.2 | 181       |
| 24 | Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1428-1436.                                  | 1.9 | 181       |
| 25 | Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e18-e27.  | 2.2 | 173       |
| 26 | Cardiovascular Drug Development. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1567-1582.   | 1.2 | 168       |
| 27 | Economic Assessment of Low-Molecular-Weight Heparin (Enoxaparin) Versus Unfractionated Heparin in Acute Coronary Syndrome Patients. <i>Circulation</i> , 1998, 97, 1702-1707.  | 1.6 | 163       |
| 28 | Complication Rates After Hip or Knee Arthroplasty in Morbidly Obese Patients. <i>Clinical Orthopaedics and Related Research</i> , 2013, 471, 3358-3366.  | 0.7 | 160       |
| 29 | Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2271-2281.   | 1.2 | 159       |
| 30 | Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 3377-3385. | 1.0 | 154       |
| 31 | Comparison of the Oral Direct Thrombin Inhibitor Ximelagatran With Enoxaparin as Prophylaxis Against Venous Thromboembolism After Total Knee Replacement. <i>Archives of Internal Medicine</i> , 2001, 161, 2215.  | 4.3 | 150       |
| 32 | Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation. <i>JAMA Neurology</i> , 2019, 76, 764.   | 4.5 | 147       |
| 33 | Clinical Significance of Thrombocytopenia During a Non-ST-Elevation Acute Coronary Syndrome. <i>Circulation</i> , 1999, 99, 2892-2900.   | 1.6 | 146       |
| 34 | Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. <i>Lancet Neurology</i> , 2018, 17, 1053-1060.   | 4.9 | 146       |
| 35 | Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 130.   | 3.8 | 146       |
| 36 | Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 1873-1880.  | 1.0 | 145       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial. <i>Stroke</i> , 2014, 45, 1739-1747.   | 1.0 | 142       |
| 38 | Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. <i>Journal of the American College of Cardiology</i> , 1998, 32, 311-319.  | 1.2 | 141       |
| 39 | Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2119-2130.   | 1.9 | 141       |
| 40 | Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2016, 133, 352-360.  | 1.6 | 141       |
| 41 | On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin. <i>Circulation</i> , 2016, 134, 37-47.   | 1.6 | 134       |
| 42 | Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). <i>American Heart Journal</i> , 2015, 170, 675-682.e8. | 1.2 | 128       |
| 43 | Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.   | 1.6 | 127       |
| 44 | Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Lancet, The</i> , 2015, 385, 2363-2370.     | 6.3 | 123       |
| 45 | Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019, 139, 1134-1145.  | 1.6 | 118       |
| 46 | Glycoprotein IIb/IIIa Integrin Blockade. <i>Circulation</i> , 1998, 98, 2629-2635.  | 1.6 | 117       |
| 47 | Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry. <i>International Journal of Stroke</i> , 2016, 11, 526-533.  | 2.9 | 113       |
| 48 | Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). <i>American Heart Journal</i> , 2018, 199, 83-91.  | 1.2 | 104       |
| 49 | Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2013, 6, 740-747.  | 1.6 | 102       |
| 50 | Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH). <i>Drug Safety</i> , 2011, 34, 243-252.  | 1.4 | 98        |
| 51 | Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1841-1854.  | 1.6 | 96        |
| 52 | Efficacy and Safety of Low Molecular Weight Heparin (Ardeparin Sodium) Compared to Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement Surgery: A Double-blind, Dose-ranging Study. <i>Thrombosis and Haemostasis</i> , 1997, 77, 032-038.   | 1.8 | 96        |
| 53 | Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2014, 3, e000521.   | 1.6 | 94        |
| 54 | Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. <i>American Heart Journal</i> , 2000, 140, 74-80.   | 1.2 | 83        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. <i>European Stroke Journal</i> , 2016, 1, 146-154.   | 2.7 | 83        |
| 56 | Modifiable Risk Factors for Vascular Access Site Complications in the IMPACT II Trial of Angioplasty With Versus Without Eptifibatide. <i>Journal of the American College of Cardiology</i> , 1998, 31, 1518-1524.                                | 1.2 | 80        |
| 57 | Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2019, 50, 3184-3190.  | 1.0 | 78        |
| 58 | Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2019, 5, 145-152. | 1.8 | 75        |
| 59 | Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients) Tj ETQq1 1 0.784314 rgBT /Overlock 10  | 0.7 | 74        |
| 60 | Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. <i>Stroke</i> , 2019, 50, 2477-2485.  | 1.0 | 72        |
| 61 | Novel oral anticoagulants and reversal agents: Considerations for clinical development. <i>American Heart Journal</i> , 2015, 169, 751-757.   | 1.2 | 69        |
| 62 | Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. <i>American Heart Journal</i> , 2001, 141, 226-233.   | 1.2 | 68        |
| 63 | Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. <i>International Journal of Cardiology</i> , 2013, 167, 1772-1782.                           | 0.8 | 67        |
| 64 | Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. <i>American Heart Journal</i> , 1999, 138, S317-S326.  | 1.2 | 59        |
| 65 | Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization. <i>Circulation</i> , 2020, 142, 2219-2230.  | 1.6 | 58        |
| 66 | Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial. <i>Stroke</i> , 2020, 51, 1797-1804.  | 1.0 | 54        |
| 67 | Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. <i>Heart Rhythm</i> , 2014, 11, 925-932.  | 0.3 | 52        |
| 68 | Rivaroxaban for treatment of pediatric venous thromboembolism. An Einsteinâ€r phase 3 doseâ€r exposureâ€r response evaluation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1672-1685.  | 1.9 | 52        |
| 69 | Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. <i>American Heart Journal</i> , 2016, 179, 77-86.   | 1.2 | 51        |
| 70 | Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). <i>Blood Advances</i> , 2020, 4, 6250-6258.   | 2.5 | 49        |
| 71 | Efficacy of abciximab readministration in coronary intervention. <i>American Journal of Cardiology</i> , 2000, 85, 435-440.   | 0.7 | 48        |
| 72 | Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. <i>American Heart Journal</i> , 2016, 178, 74-84.   | 1.2 | 48        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin for the Prevention of Venous Thromboembolism After Total Knee Arthroplasty. <i>Journal of Bone and Joint Surgery - Series A</i> , 2005, 87, 2169.  | 1.4 | 47        |
| 74 | Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1914-1919.   | 1.9 | 46        |
| 75 | Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy. <i>Annals of Internal Medicine</i> , 2013, 158, 861.   | 2.0 | 46        |
| 76 | Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 1673-1682.  | 0.7 | 46        |
| 77 | The effects of rivaroxaban on the complications of surgery after total hip or knee replacement. <i>Journal of Bone and Joint Surgery: British Volume</i> , 2012, 94-B, 1573-1578.   | 3.4 | 43        |
| 78 | End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 470-478.   | 0.9 | 39        |
| 79 | Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> , 2020, 141, 1141-1151.   | 1.6 | 39        |
| 80 | Hemodilution With Other Blood Reinfusion Techniques in Total Hip Arthroplasty. <i>Clinical Orthopaedics and Related Research</i> , 1997, 339, 132-139.  | 0.7 | 38        |
| 81 | Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source. <i>JAMA Neurology</i> , 2020, 77, 1233.   | 4.5 | 37        |
| 82 | Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. <i>American Heart Journal</i> , 2002, 144, 151-158.   | 1.2 | 36        |
| 83 | Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. <i>Heart</i> , 2016, 102, 1036-1043.   | 1.2 | 36        |
| 84 | Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). <i>American Journal of Cardiology</i> , 2017, 120, 588-594.   | 0.7 | 36        |
| 85 | Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?. <i>American Heart Journal</i> , 2018, 199, 59-67.   | 1.2 | 36        |
| 86 | Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , 2019, 140, 1451-1459.  | 1.6 | 36        |
| 87 | Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). <i>Blood Advances</i> , 2020, 4, 4632-4639.   | 2.5 | 35        |
| 88 | Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. <i>European Heart Journal</i> , 2019, 40, 3771-3778a.  | 1.0 | 34        |
| 89 | Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non- $\text{ST}$ -segment elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2001, 88, 1230-1234. | 0.7 | 33        |
| 90 | Incidence of neuraxial haematoma after total hip or knee surgery: <scp>RECORD</scp> programme (rivaroxaban vs. enoxaparin). <i>Acta Anaesthesiologica Scandinavica</i> , 2013, 57, 565-572.   | 0.7 | 33        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease. <i>JAMA Cardiology</i> , 2021, 6, 21-29.  | 3.0 | 33        |
| 92  | The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. <i>Journal of Thrombosis and Thrombolysis</i> , 2002, 14, 91-101. | 1.0 | 31        |
| 93  | Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. <i>Europace</i> , 2016, 18, 1135-1142.   | 0.7 | 31        |
| 94  | Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021, 78, 14-23.   | 1.2 | 31        |
| 95  | New heparin dosing recommendations for patients with acute coronary syndromes. <i>American Journal of Medicine</i> , 2001, 110, 641-650.  | 0.6 | 30        |
| 96  | Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin. <i>Circulation</i> , 2017, 135, 1001-1003.   | 1.6 | 30        |
| 97  | Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1519-1528.  | 1.2 | 30        |
| 98  | Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. <i>Journal of the American College of Cardiology</i> , 2021, 78, 317-326.   | 1.2 | 30        |
| 99  | Heparin dosing and outcome in acute coronary syndromes: The GUSTO-IIb experience. <i>American Heart Journal</i> , 2002, 144, 73-80.   | 1.2 | 28        |
| 100 | Benefit&ndash;risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. <i>Vascular Health and Risk Management</i> , 2014, 10, 157.   | 1.0 | 28        |
| 101 | Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 412-422.   | 0.7 | 28        |
| 102 | Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study. <i>Thrombosis Journal</i> , 2018, 16, 34.   | 0.9 | 28        |
| 103 | Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 296-307.  | 0.8 | 28        |
| 104 | Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source. <i>JAMA Neurology</i> , 2021, 78, 11.   | 4.5 | 28        |
| 105 | The discovery and development of rivaroxaban. <i>Annals of the New York Academy of Sciences</i> , 2011, 1222, 64-75.  | 1.8 | 27        |
| 106 | Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 2273-2279.   | 0.7 | 27        |
| 107 | Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists. <i>Current Opinion in Hematology</i> , 1999, 6, 334-341.   | 1.2 | 26        |
| 108 | Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2020, 51, 938-943.  | 1.0 | 25        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial. <i>European Journal of Neurology</i> , 2020, 27, 841-848.         | 1.7 | 25        |
| 110 | Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. <i>Circulation</i> , 2021, 144, 1104-1116.                           | 1.6 | 25        |
| 111 | Relation between inhibition of platelet aggregation and clinical outcomes. <i>American Heart Journal</i> , 1998, 136, s43-s50.  | 1.2 | 24        |
| 112 | ORAL DIRECT THROMBIN INHIBITOR XIMELAGATRAN COMPARED WITH WARFARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE ARTHROPLASTY. <i>Journal of Bone and Joint Surgery - Series A</i> , 2005, 87, 2169-2177.     | 1.4 | 24        |
| 113 | Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). <i>American Journal of Cardiology</i> , 2001, 88, 541-546.            | 0.7 | 23        |
| 114 | Branch atheromatous disease diagnosed as embolic stroke of undetermined source: A sub-analysis of NAVIGATE ESUS. <i>International Journal of Stroke</i> , 2019, 14, 915-922.  | 2.9 | 22        |
| 115 | Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1694-1702.   | 1.1 | 21        |
| 116 | Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e008755.     | 1.6 | 21        |
| 117 | Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. <i>Circulation</i> , 2021, 144, 1831-1841.                  | 1.6 | 19        |
| 118 | Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1768-1778.  | 1.2 | 19        |
| 119 | Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombotic-mediated conditions. <i>Annals of the New York Academy of Sciences</i> , 2013, 1291, 42-55.                                    | 1.8 | 18        |
| 120 | High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2020, 51, 2386-2394.  | 1.0 | 18        |
| 121 | Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e181-e189.                    | 0.8 | 18        |
| 122 | Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 1997, 11, 875-877. | 0.6 | 17        |
| 123 | Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104936.                 | 0.7 | 17        |
| 124 | The discovery of rivaroxaban: translating preclinical assessments into clinical practice. <i>Frontiers in Pharmacology</i> , 2013, 4, 145.  | 1.6 | 15        |
| 125 | Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. <i>Stroke</i> , 2020, 51, 2901-2909.   | 1.0 | 15        |
| 126 | Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. <i>Cardiovascular Research</i> , 2021, 117, 942-949.   | 1.8 | 15        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Progress in point-of-care laboratory testing for assessing platelet function. <i>American Heart Journal</i> , 1998, 136, s51-s65.   | 1.2 | 14        |
| 128 | Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis. <i>Thrombosis Journal</i> , 2018, 16, 29.  | 0.9 | 14        |
| 129 | Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 20-29.  | 1.0 | 14        |
| 130 | Antithrombotic therapy after prosthetic cardiac valve implantation: Potential novel antithrombotic therapies. <i>American Heart Journal</i> , 2001, 142, 7-13.  | 1.2 | 13        |
| 131 | Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. <i>European Heart Journal</i> , 2021, 42, 4040-4048.   | 1.0 | 13        |
| 132 | Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. <i>Thrombosis Research</i> , 2017, 156, 184-190.   | 0.8 | 11        |
| 133 | Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. <i>Clinical Cardiology</i> , 2018, 41, 39-45.   | 0.7 | 11        |
| 134 | Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019, 14, 270-281.   | 2.9 | 11        |
| 135 | Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2021, 77, 511-525.   | 1.2 | 11        |
| 136 | Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. <i>JAMA Network Open</i> , 2022, 5, e2215580.  | 2.8 | 11        |
| 137 | Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K) <i>Tj ETQq1 1 0.784314 rgBT /Over</i><br><i>Cardiology</i> , 2017, 120, 1837-1840. | 0.7 | 10        |
| 138 | Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. <i>International Journal of Cardiology</i> , 2018, 257, 78-83.   | 0.8 | 10        |
| 139 | Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 1-11.  | 1.0 | 10        |
| 140 | Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacyâ€. <i>European Heart Journal</i> , 2013, 34, 1621-1629.  | 1.0 | 9         |
| 141 | Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 805-814.   | 1.3 | 9         |
| 142 | Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4. <i>Blood</i> , 2008, 112, 35-35.   | 0.6 | 9         |
| 143 | Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .  | 1.6 | 8         |
| 144 | Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial. <i>Stroke</i> , 2022, 53, 45-52.  | 1.0 | 8         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery. <i>Blood</i> , 2008, 112, 436-436.  | 0.6 | 8         |
| 146 | Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy. <i>International Journal of Stroke</i> , 2022, 17, 799-805.   | 2.9 | 8         |
| 147 | Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. <i>Journal of the American Heart Association</i> , 2022, 11, .   | 1.6 | 8         |
| 148 | Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source. <i>Stroke</i> , 2020, 51, 2139-2147.   | 1.0 | 7         |
| 149 | Current Knowledge of the Platelet Glycoprotein IIb/IIIa Receptor Antagonists for the Treatment of Coronary Artery Disease. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2000, 30, 27-43.   | 0.5 | 6         |
| 150 | Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. <i>American Heart Journal</i> , 2018, 200, 102-109.  | 1.2 | 6         |
| 151 | Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2019, 13, 175394471986364.   | 1.0 | 6         |
| 152 | Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 12-19.   | 1.0 | 6         |
| 153 | Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. <i>Heart</i> , 2021, 107, 1130-1137.   | 1.2 | 6         |
| 154 | TREATMENT OF ESTABLISHED DEEP VEIN THROMBOSIS: A REVIEW OF THE THERAPEUTIC ARMAMENTARIUM. <i>Orthopedics</i> , 1995, 18, 18-20.  | 0.5 | 5         |
| 155 | Thrombin and fibrin activity in patients treated with enoxaparin, ticlopidine and aspirin versus the conventional coumadin regimen after elective stenting: The ENTICES trial. <i>Journal of the American College of Cardiology</i> , 1996, 27, 334.   | 1.2 | 4         |
| 156 | Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF. <i>American Heart Journal</i> , 2021, 236, 4-12.  | 1.2 | 4         |
| 157 | Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease. <i>International Journal of Cardiology</i> , 2021, 337, 9-15.  | 0.8 | 4         |
| 158 | Analysis of the occurrence and clinical significance of thrombocytopenis with c7E3 (abciximab) in the EPIC trial. <i>Journal of the American College of Cardiology</i> , 1996, 27, 82.   | 1.2 | 3         |
| 159 | Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1193-1205. | 1.9 | 3         |
| 160 | Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD. <i>Vascular Medicine</i> , 2022, 27, 343-349.  | 0.8 | 3         |
| 161 | Vascular access site complications during angioplasty with glycoprotein IIb/IIIa receptor inhibition in the IMPACT II trial. <i>Journal of the American College of Cardiology</i> , 1996, 27, 360.   | 1.2 | 2         |
| 162 | CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH ATRIAL FIBRILLATION AND SIGNIFICANT VALVULAR LESIONS: EXPERIENCE FROM THE ROCKET AF TRIAL. <i>Journal of the American College of Cardiology</i> , 2013, 61, E282.  | 1.2 | 2         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. <i>Cardiology and Therapy</i> , 2019, 8, 283-295.   | 1.1 | 2         |
| 164 | Regional, sex, and age differences in diagnostic testing among participants in the NAVIGATE-ESUS trial. <i>International Journal of Stroke</i> , 2021, 16, 55-62.   | 2.9 | 2         |
| 165 | Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment. <i>Journal of the American College of Cardiology</i> , 2021, 78, 757-759.   | 1.2 | 2         |
| 166 | Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation." <i>Circulation</i> , 2016, 134, e7-8. | 1.6 | 1         |
| 167 | Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF. <i>Heart Rhythm O2</i> , 2021, 2, 215-222.  | 0.6 | 1         |
| 168 | Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial. <i>Atherosclerosis</i> , 2021, 331, 38-44.  | 0.4 | 1         |
| 169 | Abstract 14170: Reduction in Venous Thromboembolism With Rivaroxaban versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. <i>Circulation</i> , 2020, 142, .                                | 1.6 | 1         |
| 170 | Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. <i>Blood Advances</i> , 2018, 2, 3193-3195.   | 2.5 | 0         |
| 171 | Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e022485.  | 1.6 | 0         |
| 172 | Bleeding Indicators and Wound Complications with Ximelagatran and Warfarin after TKR: Findings from 3 Clinical Trials.. <i>Blood</i> , 2004, 104, 1771-1771.  | 0.6 | 0         |